Trevi Therapeutics, Inc. (TRVI) Net income 2018–2025
Trevi Therapeutics, Inc. (TRVI) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$42.8MFY2025 · since FY2018: -$20.5M → -$42.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$42.8M | +10.8% |
| FY2024 | -$47.9M | -64.8% |
| FY2023 | -$29.1M | +0.3% |
| FY2022 | -$29.2M | +14.1% |
| FY2021 | -$33.9M | -3.6% |
| FY2020 | -$32.8M | -25.8% |
| FY2019 | -$26.1M | -26.8% |
| FY2018 | -$20.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More TRVI financial trends
TRVI RevenueTRVI Net marginTRVI Gross profitTRVI Gross marginTRVI Operating incomeTRVI Operating marginTRVI Operating cash flowTRVI Free cash flowTRVI Capital expendituresTRVI Return on equityTRVI Stock buybacksTRVI Dividends paidTRVI Total assetsTRVI Total liabilitiesTRVI Shareholders’ equityTRVI overview →